Education
About Us
Working with TipRanks
Follow Us
Kazia Therapeutics Limited (KZIA)
NASDAQ:KZIA
KZIA Stock Chart & Stats
$6.44
-$0.01(-0.57%)
At close: 4:00 PM EST
$6.44
-$0.01(-0.57%)
Day’s Range― - ―
52-Week Range$2.86 - $17.40
Previous CloseN/A
Volume31.49K
Average Volume (3M)209.48K
Market Cap
$81.17M
Enterprise Value$9.23M
Total Cash (Recent Filing)$3.06M
Total Debt (Recent Filing)$140.74K
Price to Earnings (P/E)―
Beta1.55
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,335,992
10 Day Avg. Volume60,839
30 Day Avg. Volume209,481
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.11
Enterprise Value/Revenue3.69
Enterprise Value/Gross Profit3.69
Enterprise Value/Ebitda-0.34
Forecast
1Y Price Target
$19.00Price Target Upside195.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Early Clinical Activity In Triple‑negative Breast CancerEarly Phase 1b data showed a marked tumor volume reduction in a patient with triple‑negative breast cancer, suggesting potential single‑agent activity that could translate into broader clinical value if additional patients show similar responses.
Immuno‑oncology Combination PotentialEx vivo and combination findings indicate paxalisib reduces circulating tumor cell clusters and activates anti‑tumor immune pathways, supporting combinations with immunotherapies that could expand the drug’s addressable market.
Strengthened Financial Flexibility To Support DevelopmentA recent equity raise improved the company’s financial flexibility and should support continued clinical development across the pipeline, reducing near‑term financing pressure.
Bears Say
Clinical Trial Endpoint ShortfallFailure to meet primary endpoints in Phase 2 studies raises questions about clinical benefit and could undermine confidence in the drug’s efficacy profile.
Regulatory Uncertainty And Potential For Additional TrialsThere is uncertainty whether regulators will require a pre‑approval pivotal study, which could delay approval timelines and increase development costs.
Share Price Volatility And Sell‑the‑news RiskSignificant share price declines on news‑driven reactions reflect investor skepticism and can make future equity funding more difficult during periods of volatility.
Kazia Therapeutics News
KZIA FAQ
What was Kazia Therapeutics Limited’s price range in the past 12 months?
Kazia Therapeutics Limited lowest stock price was $2.86 and its highest was $17.40 in the past 12 months.
What is Kazia Therapeutics Limited’s market cap?
Kazia Therapeutics Limited’s market cap is $81.17M.
When is Kazia Therapeutics Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Kazia Therapeutics Limited’s earnings last quarter?
Currently, no data Available
Is Kazia Therapeutics Limited overvalued?
According to Wall Street analysts Kazia Therapeutics Limited’s price is currently Undervalued.
Does Kazia Therapeutics Limited pay dividends?
Kazia Therapeutics Limited does not currently pay dividends.
What is Kazia Therapeutics Limited’s EPS estimate?
Kazia Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kazia Therapeutics Limited have?
Kazia Therapeutics Limited has 11,335,992 shares outstanding.
What happened to Kazia Therapeutics Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Kazia Therapeutics Limited?
Currently, no hedge funds are holding shares in KZIA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kazia Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$19.00 (195.03% Upside)
$19.00 (195.03% Upside)
Hedge Fund Trend
Decreased
By 36.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-73.42%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-33.34%
Trailing 12-Months
Company Description
Kazia Therapeutics Limited
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
KZIA Stock 12 Month Forecast
Average Price Target
$19.00
▲(195.03% Upside)
Technical Analysis
Phio Pharmaceuticals
―
XTL Biopharmaceuticals Sponsored ADR
―
Marker Therapeutics
―
Galecto
―
TransCode Therapeutics
―
Ownership Overview
―
Insiders
0.01% Mutual Funds
7.07% Other Institutional Investors
92.92% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---